share_log

Tilray Brands, Inc.'s (NASDAQ:TLRY) Shift From Loss To Profit

Simply Wall St ·  Sep 5 01:37

With the business potentially at an important milestone, we thought we'd take a closer look at Tilray Brands, Inc.'s (NASDAQ:TLRY) future prospects. Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The US$1.4b market-cap company announced a latest loss of US$245m on 31 May 2024 for its most recent financial year result. As path to profitability is the topic on Tilray Brands' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company.

Consensus from 12 of the American Pharmaceuticals analysts is that Tilray Brands is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$30m in 2027. So, the company is predicted to breakeven approximately 3 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 83%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

big
NasdaqGS:TLRY Earnings Per Share Growth September 4th 2024

We're not going to go through company-specific developments for Tilray Brands given that this is a high-level summary, but, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there's one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 9.3% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Tilray Brands which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Tilray Brands, take a look at Tilray Brands' company page on Simply Wall St. We've also put together a list of pertinent aspects you should look at:

  1. Valuation: What is Tilray Brands worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Tilray Brands is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Tilray Brands's board and the CEO's background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment